Biotherapy Services Limited - Accounts to registrar (filleted) - small 18.2

Biotherapy Services Limited - Accounts to registrar (filleted) - small 18.2


IRIS Accounts Production v21.2.0.376 08566712 Board of Directors Board of Directors 1.7.20 30.6.21 30.6.21 20.8.21 false true false false false true false Auditors Opinion iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pure085667122020-06-30085667122021-06-30085667122020-07-012021-06-30085667122019-06-30085667122019-07-012020-06-30085667122020-06-3008566712ns16:EnglandWales2020-07-012021-06-3008566712ns15:PoundSterling2020-07-012021-06-3008566712ns11:Director12020-07-012021-06-3008566712ns11:Director22020-07-012021-06-3008566712ns11:PrivateLimitedCompanyLtd2020-07-012021-06-3008566712ns11:SmallEntities2020-07-012021-06-3008566712ns11:Audited2020-07-012021-06-3008566712ns11:SmallCompaniesRegimeForDirectorsReport2020-07-012021-06-3008566712ns11:SmallCompaniesRegimeForAccounts2020-07-012021-06-3008566712ns11:FullAccounts2020-07-012021-06-300856671212020-07-012021-06-3008566712ns11:Director32020-07-012021-06-3008566712ns11:Director42020-07-012021-06-3008566712ns11:Director52020-07-012021-06-3008566712ns11:Director62020-07-012021-06-3008566712ns11:CompanySecretary12020-07-012021-06-3008566712ns11:RegisteredOffice2020-07-012021-06-3008566712ns6:CurrentFinancialInstruments2021-06-3008566712ns6:CurrentFinancialInstruments2020-06-3008566712ns6:Non-currentFinancialInstruments2021-06-3008566712ns6:Non-currentFinancialInstruments2020-06-3008566712ns6:ShareCapital2021-06-3008566712ns6:ShareCapital2020-06-3008566712ns6:SharePremium2021-06-3008566712ns6:SharePremium2020-06-3008566712ns6:RetainedEarningsAccumulatedLosses2021-06-3008566712ns6:RetainedEarningsAccumulatedLosses2020-06-3008566712ns6:IntangibleAssetsOtherThanGoodwill2020-07-012021-06-3008566712ns6:PatentsTrademarksLicencesConcessionsSimilar2020-07-012021-06-3008566712ns6:ComputerSoftware2020-07-012021-06-3008566712ns6:PlantMachinery2020-07-012021-06-3008566712ns6:FurnitureFittings2020-07-012021-06-3008566712ns6:IntangibleAssetsOtherThanGoodwill2020-06-3008566712ns6:IntangibleAssetsOtherThanGoodwill2021-06-3008566712ns6:IntangibleAssetsOtherThanGoodwill2020-06-3008566712ns6:PlantMachinery2020-06-3008566712ns6:PlantMachinery2021-06-3008566712ns6:PlantMachinery2020-06-3008566712ns6:LeasedAssetsHeldAsLesseens6:PlantMachinery2020-06-3008566712ns6:LeasedAssetsHeldAsLesseens6:PlantMachinery2020-07-012021-06-3008566712ns6:LeasedAssetsHeldAsLesseens6:PlantMachinery2021-06-3008566712ns6:LeasedAssetsHeldAsLesseens6:PlantMachinery2020-06-3008566712ns6:CurrentFinancialInstrumentsns6:WithinOneYear2021-06-3008566712ns6:CurrentFinancialInstrumentsns6:WithinOneYear2020-06-3008566712ns6:CurrentFinancialInstrumentsns6:HirePurchaseContractsns6:WithinOneYear2021-06-3008566712ns6:CurrentFinancialInstrumentsns6:HirePurchaseContractsns6:WithinOneYear2020-06-3008566712ns6:HirePurchaseContractsns6:BetweenOneFiveYears2021-06-3008566712ns6:HirePurchaseContractsns6:BetweenOneFiveYears2020-06-3008566712ns6:HirePurchaseContracts2021-06-3008566712ns6:HirePurchaseContracts2020-06-3008566712ns6:WithinOneYear2021-06-3008566712ns6:WithinOneYear2020-06-3008566712ns6:BetweenOneFiveYears2021-06-3008566712ns6:BetweenOneFiveYears2020-06-3008566712ns6:AllPeriods2021-06-3008566712ns6:AllPeriods2020-06-300856671212020-07-012021-06-30
REGISTERED NUMBER: 08566712 (England and Wales)















Financial Statements for the Year Ended 30 June 2021

for

Biotherapy Services Limited

Biotherapy Services Limited (Registered number: 08566712)






Contents of the Financial Statements
for the Year Ended 30 June 2021




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


Biotherapy Services Limited

Company Information
for the Year Ended 30 June 2021







DIRECTORS: Mrs J M Hadfield
Mr J A Rickard
Mr K Golchin
Mr J Chiplin
Mr N J Mettyear
Mr R H Morton





SECRETARY: Derringtons Limited





REGISTERED OFFICE: Gainsborough House
59-60 Thames Street
Windsor
SL4 1TX





REGISTERED NUMBER: 08566712 (England and Wales)





AUDITORS: WP Audit Limited
Statutory Auditors
5a Frascati Way
Maidenhead
Berkshire
SL6 4UY

Biotherapy Services Limited (Registered number: 08566712)

Balance Sheet
30 June 2021

30.6.21 30.6.20
Notes £    £   
FIXED ASSETS
Intangible assets 4 23,061 31,140
Tangible assets 5 17,866 15,558
40,927 46,698

CURRENT ASSETS
Stocks 38,498 32,451
Debtors 6 395,551 431,808
Cash at bank 187,782 1,143,606
621,831 1,607,865
CREDITORS
Amounts falling due within one year 7 (318,432 ) (395,091 )
NET CURRENT ASSETS 303,399 1,212,774
TOTAL ASSETS LESS CURRENT LIABILITIES 344,326 1,259,472

CREDITORS
Amounts falling due after more than one
year

8

(1,019,342

)

(948,375

)
NET (LIABILITIES)/ASSETS (675,016 ) 311,097

CAPITAL AND RESERVES
Called up share capital 19,492 19,492
Share premium 3,025,232 3,025,232
Retained earnings (3,719,740 ) (2,733,627 )
(675,016 ) 311,097

Biotherapy Services Limited (Registered number: 08566712)

Balance Sheet - continued
30 June 2021


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 19 August 2021 and were signed on its behalf by:




Mrs J M Hadfield - Director



Mr J A Rickard - Director


Biotherapy Services Limited (Registered number: 08566712)

Notes to the Financial Statements
for the Year Ended 30 June 2021

1. STATUTORY INFORMATION

Biotherapy Services Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102
"The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the
provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have
been prepared under the historical cost convention.

The directors have considered the company's cashflows for the next 12 months.The directors remain confident about the company's future and are committed to its continued support. The directors consider the company retains sufficient working capital to continue trading for the foreseeable future.

Accordingly, the directors have confirmed that it is appropriate to adopt the going concern basis for the preparation of these financial statements.

Significant judgements and estimates
In the application of the company's accounting policies the directors are required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

The company does not make significant estimates and assumptions concerning the future.

Biotherapy Services Limited (Registered number: 08566712)

Notes to the Financial Statements - continued
for the Year Ended 30 June 2021

2. ACCOUNTING POLICIES - continued

Turnover
Turnover is recognised on provision of services and goods sold at the fair value of the consideration received or receivable for services and goods provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Patents and licences are being amortised evenly over their estimated useful life of eleven years.

Computer software is being amortised evenly over its estimated useful life of five years.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life or, if held under a finance lease, over the lease term, whichever is the shorter.
Plant and machinery - 20% on reducing balance
Fixtures and fittings - 33% on reducing balance

Government grants
The company received income from the Government Coronavirus Job Retention Scheme. Government grants are recognised in the income statement in the same period as the related expenditure.

Stocks
Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

Stocks held for distribution at no or nominal consideration are measured at the lower of replacement cost and cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

Financial instruments
Basic financial instruments are recognised at amortised cost using the effective interest method, except for investments in non-convertible preference and non-puttable preference and ordinary shares, which are measured at fair value, with changes recognised in profit or loss. Derivative financial instruments are initially recorded at cost and thereafter at fair value, with changes recognised in profit and loss.


Biotherapy Services Limited (Registered number: 08566712)

Notes to the Financial Statements - continued
for the Year Ended 30 June 2021

2. ACCOUNTING POLICIES - continued
Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Research and development
Research expenditure is written off against profits in the year in which it is incurred. Identifiable development expenditure is capitalised to the extent that the technical, commercial and financial feasibility can be demonstrated.

Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Hire purchase and leasing commitments
Assets obtained under hire purchase contracts or finance leases are capitalised in the balance sheet. Those held under hire purchase contracts are depreciated over their estimated useful lives. Those held under finance leases are depreciated over their estimated useful lives or the lease term, whichever is the shorter.

The interest element of these obligations is charged to profit or loss over the relevant period. The capital element of the future payments is treated as a liability.

Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Biotherapy Services Limited (Registered number: 08566712)

Notes to the Financial Statements - continued
for the Year Ended 30 June 2021

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 12 (2020 - 8 ) .

4. INTANGIBLE FIXED ASSETS
Other
intangible
assets
£   
COST
At 1 July 2020
and 30 June 2021 87,480
AMORTISATION
At 1 July 2020 56,340
Charge for year 8,079
At 30 June 2021 64,419
NET BOOK VALUE
At 30 June 2021 23,061
At 30 June 2020 31,140

Biotherapy Services Limited (Registered number: 08566712)

Notes to the Financial Statements - continued
for the Year Ended 30 June 2021

5. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 1 July 2020 44,219
Additions 10,093
Disposals (1,629 )
At 30 June 2021 52,683
DEPRECIATION
At 1 July 2020 28,661
Charge for year 6,964
Eliminated on disposal (808 )
At 30 June 2021 34,817
NET BOOK VALUE
At 30 June 2021 17,866
At 30 June 2020 15,558

Fixed assets, included in the above, which are held under hire purchase contracts are as follows:

Plant and
machinery
etc
£   
COST
At 1 July 2020
and 30 June 2021 13,500
DEPRECIATION
At 1 July 2020 6,588
Charge for year 1,382
At 30 June 2021 7,970
NET BOOK VALUE
At 30 June 2021 5,530
At 30 June 2020 6,912

Biotherapy Services Limited (Registered number: 08566712)

Notes to the Financial Statements - continued
for the Year Ended 30 June 2021

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30.6.21 30.6.20
£    £   
Trade debtors 25,472 22,261
Other debtors 370,079 409,547
395,551 431,808

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30.6.21 30.6.20
£    £   
Hire purchase contracts (see note 9) 2,048 9,028
Trade creditors 116,160 197,343
Taxation and social security 19,697 52,821
Other creditors 180,527 135,899
318,432 395,091

8. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR
30.6.21 30.6.20
£    £   
Hire purchase contracts (see note 9) - 1,033
Other creditors 1,019,342 947,342
1,019,342 948,375

9. LEASING AGREEMENTS

Minimum lease payments fall due as follows:

Hire purchase contracts
30.6.21 30.6.20
£    £   
Net obligations repayable:
Within one year 2,048 9,028
Between one and five years - 1,033
2,048 10,061

Biotherapy Services Limited (Registered number: 08566712)

Notes to the Financial Statements - continued
for the Year Ended 30 June 2021

9. LEASING AGREEMENTS - continued

Non-cancellable operating leases
30.6.21 30.6.20
£    £   
Within one year 49,345 30,839
Between one and five years - 4,433
49,345 35,272

10. SECURED DEBTS

The following secured debts are included within creditors:

30.6.21 30.6.20
£    £   
Hire purchase contracts 2,048 10,061

11. DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

The Report of the Auditors was unqualified.

Philippa Duckworth BSc FCCA (Senior Statutory Auditor)
for and on behalf of WP Audit Limited

12. POST BALANCE SHEET EVENTS

Post year end an investment of £1,500,000 has been received. This is sufficient based on the current run rate for the business to continue to trade for the next 12 months.

13. ULTIMATE CONTROLLING PARTY

There is no ultimate controlling party.